KOSDAQBiotech & Pharma376930

Noul

₩1,910▲ 0.90%2026-11-18 close
Market Cap
₩21.7B
Turnover
₩2.1B
Volume
1.1M
Shares out.
11.4M
PER
—
PBR
1.7×
EPS
-₩1,566
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Device rollout vs. persistent losses at Noul

Noul's quarterly sales swung sharply through 2026, and operating losses have persisted for five consecutive quarters from Q3 2025 through Q3 2026.

  1. 1

    Revenue in 2025 was KRW 5.12 billion, the largest year in 2022 to 2025, while the operating loss for the same year was KRW 20.1 billion.

  2. 2

    The operating loss narrowed from KRW 22.8 billion in 2024 to KRW 20.1 billion in 2025, while operating cash flow stood at -KRW 20.5 billion in 2025.

  3. 3

    Q3 2026 revenue was KRW 512 million, down 49.3% from the prior quarter, and the operating loss for the quarter was KRW 4.52 billion.

  4. 4

    The company said its 2026 device sales guidance of 500 units is on track, and because 91% of placements are purchase-conditional, the pace of conversion into recognized sales is the key variable.

  5. 5

    110,000 new shares from a third-party allotment rights issue were listed on November 18, 2026, and all are subject to a lock-up through November 17, 2027.

02

Business structure

Noul was founded in 2015 and listed on KOSDAQ in 2022, operating as a healthcare company focused on diagnostics. Its core platform is miLab, a combination of devices and cartridges that automatically diagnoses conditions such as malaria and blood cancers from a single drop of blood.

The product line is split into malaria cartridges, the blood analysis cartridge (BCM), and the cervical cancer cell analysis cartridge (CER), and CER made its first shipment in September 2025.

The revenue model places devices in the field first and then earns recurring sales from consumables such as diagnostic cartridges. Based on its European CE certification, the company said it has completed product registrations in Africa, Southeast Asia, Europe and the United States.

The 2026 distribution target is 79 countries, with a stated goal of lifting US and EU sales to more than 60% of the mix. On the customer side, Noul is joining public health authorities, including a role as a partner in the restructuring of Panama's national health system.

The company says Indonesia and the United Kingdom have limited alternatives to its products given their island-nation characteristics. Because device placements and repeat cartridge purchases move together, the installed base serves as a leading indicator for sales.

Since the product line is concentrated on the miLab platform, a quality or certification problem with one cartridge could spread across the whole company. A precision cancer diagnostic version, miLab Rx, is still in development.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.1B-₩3.9B−363.9%
2025Q4₩1.2B-₩6.7B−537.4%
2026Q1₩300M-₩4.9B−1507.6%
2026Q2₩1B-₩4.8B−476.2%
2026Q3₩500M-₩4.5B−882.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩500M-₩15.6B-₩13.7B−2884.8%−120.0%126.9%
2023₩2.7B-₩16.1B-₩16.3B−590.3%−38.0%29.3%
2024₩1.6B-₩22.8B-₩22.5B−1423.4%−111.4%87.5%
2025₩5.1B-₩20.1B-₩20B−392.0%−77.7%52.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue moved from KRW 542 million in 2022 to KRW 2.73 billion in 2023, KRW 1.6 billion in 2024 and KRW 5.12 billion in 2025. Revenue rose 404.5% in 2023 and fell 41.4% in 2024 before rising 219.8% in 2025, making 2025 the largest year in the 2022 to 2025 span.

The operating loss was KRW 15.6 billion in 2022, KRW 16.1 billion in 2023, KRW 22.8 billion in 2024 and KRW 20.1 billion in 2025. The loss widened year on year in 2023 and 2024 and narrowed in 2025.

Operating margin was -2,884.8% in 2022, -590.3% in 2023, -1,423.4% in 2024 and -392.0% in 2025, so loss ratios were extreme in years when sales were small. The 2025 ratio improved from 2024 mainly because sales growth outpaced the reduction in the loss.

The loss attributable to controlling shareholders was KRW 13.7 billion in 2022, KRW 16.3 billion in 2023, KRW 22.5 billion in 2024 and KRW 20 billion in 2025, and the net loss including non-controlling interests was reported at the same amounts.

At the end of 2025, total equity was KRW 25.7 billion, of which KRW 25.7 billion was attributable to controlling shareholders, and total liabilities were KRW 13.5 billion. The debt ratio was reported at 126.9% in 2022, 29.3% in 2023, 87.5% in 2024 and 52.7% in 2025.

Operating cash flow was -KRW 14.5 billion in 2022, -KRW 15.3 billion in 2023, -KRW 20.1 billion in 2024 and -KRW 20.5 billion in 2025, so the cash outflow grew every year.

Quarterly revenue rose from KRW 1.08 billion in Q3 2025 to KRW 1.24 billion in Q4 2025 (up 15.0% quarter on quarter), then fell to KRW 322 million in Q1 2026 (down 74.1%).

Revenue recovered to KRW 1.01 billion in Q2 2026 (up 213.2%) and was KRW 512 million in Q3 2026 (down 49.3% quarter on quarter and down 52.7% year on year).

Quarterly operating losses were KRW 3.94 billion in Q3 2025, KRW 6.69 billion in Q4 2025, KRW 4.85 billion in Q1 2026, KRW 4.8 billion in Q2 2026 and KRW 4.52 billion in Q3 2026. The loss attributable to controlling shareholders for the last four quarters totaled KRW 20.8 billion.

The company said it shipped 78 devices to customers in Q1 2026, made up of 7 actual sales and 71 purchase-conditional placements, and that some revenue shifted into Q2. The company's IR material put gross margin at 60.7% in Q3 2025, and the company attributes the losses to regulatory approvals and R&D spending.

05

Industry analysis

The demand case the company presents rests on a gap in access to diagnostics. According to Noul's IR material, half of the world's population lacks access to essential health services, and diagnostic access shortfalls are cited at 47% overall and 81% in low-income countries.

Domestically, the company's materials describe a healthcare gap concentrated in the Seoul metropolitan area. A securities information site summarized Noul as focused on small and mid-sized diagnostic laboratories, using on-device AI solutions.

In digital diagnostic equipment, devices are placed first and consumable sales follow, so the installed base serves as a guide to revenue trends. On competition, the company argues that alternatives to its products are limited in most markets, but this is its own assessment based on company materials.

On regulation, the EU's stricter CE-IVDR standard is cited as a task the company is preparing for. The company's 2026 targets include 13 new country approvals, and a report said the Canadian approval for the miLab platform is in the final review stage.

Compared with listed biopharma peers, Noul's revenue scale is small and its profit and loss depend closely on the pace of device placements. The company said a confirmed government support grant of KRW 2.2 billion adds momentum separate from its own funding.

06

Outlook

The company set a 2026 device sales guidance of 500 units and said that 78 devices reached customers in Q1 2026, made up of 7 actual sales and 71 purchase-conditional placements. In the same materials, the company set targets of KRW 3 billion in 2026 revenue, KRW 5 billion in 2027 and KRW 7.5 billion in 2028.

Targets were also set for gross margin of 60% in the second half of 2026 and 70% in 2027, and for an annual profit in 2027 within the company's plan. The company aims to sign at least three partnerships in 2026 and says several collaborations are already in progress.

A report said the approval for the miLab platform in Canada is in its final stage and that talks with local distribution partners are under way.

The company attributes the weak Q1 2026 result to a partial delay from the situation in the Middle East and approval timing, and to a UK purchase order that shipped in Q2 for logistics reasons.

Reported quarterly revenue in 2026 was KRW 322 million in Q1, KRW 1.01 billion in Q2 and KRW 512 million in Q3, a wide spread across quarters. Against the KRW 3 billion annual target, the Q4 2026 revenue level will be the main variable in whether the target is met.

The November 2025 IR material also carried a target of 2,000 cumulative devices sold by 2027. The 2026 annual report will show whether revenue, second-half gross margin and device placements met the company's targets.

07

Valuation

PER
—
PBR
1.7×
ROE
-230.1%
EPS
-₩1,566
BPS
₩1,105
Dividend per share
₩0

Because the company has posted net losses over the last four quarters, a price-to-earnings ratio cannot be calculated.

The price-to-book ratio changes whenever the equity base changes, so it should be read alongside the balance sheet at the end of 2025, with total equity of KRW 25.7 billion and total liabilities of KRW 13.5 billion.

Revenue in 2025 was KRW 5.12 billion against an operating loss of KRW 20.1 billion, so valuation comparisons depend heavily on the pace of revenue growth and loss reduction. The company paid no cash dividends from 2018 through 2022, so its dividend yield has been effectively nil.

Share price weakness and market cap requirements led to repeated warnings about administrative issue designation and possible delisting, and the company carried out a 5-for-1 reverse share consolidation.

The 110,000 new shares listed on November 18, 2026 are fully subject to a lock-up through November 17, 2027, so the tradable float stays constrained for now.

For assessing the valuation, the more directly verifiable items in filings are the pace of operating margin improvement and progress toward the gross margin target, rather than multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Rising device placements

The company said that Q1 2026 actual sales of 7 units were supplemented by 71 purchase-conditional placements, bringing the total to 78 devices shipped to customers. It maintains that its 2026 device sales guidance of 500 units is on track.

Purchase-conditional placements convert into sales after approval and validation are completed, and the company's argument is that the revenue base widens once that conversion shows up.

Improving gross margin trend

Noul's IR material said gross margin improved sharply to 60.7% in Q3 2025. A securities information site noted that gross profit turned positive in Q1 2026 even as revenue declined. The company set targets of 60% gross margin for the second half of 2026 and 70% for 2027.

Overseas approvals and distribution expansion

The company targets 13 new country approvals in 2026, and a report said the miLab platform approval in Canada is in its final review stage. The 2026 distribution target is 79 countries, and signing three or more partnerships is also among its goals.

The company said a confirmed government support grant of KRW 2.2 billion adds momentum apart from its own funding.

09

Bear factors

Cumulative operating losses and cash outflow

Operating losses ranged between KRW 15.6 billion and KRW 22.8 billion from 2022 to 2025, and the 2025 operating loss was KRW 20.1 billion. Operating cash flow in the same year was -KRW 20.5 billion, a large outflow relative to KRW 5.12 billion of revenue. The loss attributable to controlling shareholders for the last four quarters totaled KRW 20.8 billion.

Volatile quarterly sales and reliance on leading indicators

Q1 2026 revenue was KRW 322 million, down 74.1%, and Q3 2026 revenue was KRW 512 million, down 49.3% from the prior quarter. According to company materials, 91% of purchase-conditional placements are leading indicators that only become revenue after approval and validation. With quarterly sales moving this much, the path to profit improvement is hard to read.

Capital raising and listing management burden

110,000 new shares from a third-party allotment rights issue were listed on November 18, 2026. Given the repeated warnings about administrative issue designation, whether the company meets the market cap requirement is the next point to check. With operating losses continuing, the need to strengthen capital could grow again.

10

Risk factors

Approval and regulatory timing

The company cited the situation in the Middle East and delays in approval timing as factors that pushed back revenue recognition in Q1 2026. The EU's stricter CE-IVDR standard applies, so how the company responds could directly affect European sales. If the Canadian approval is delayed, the North American commercialization timeline would slip with it.

Concentration on a single platform

The main products are concentrated on the single miLab platform, so devices and cartridges rely on the same technology base. A quality or certification problem in one cartridge could spread across the company. Broadening the product line across malaria, blood analysis and cervical cancer would reduce this concentration.

Funding needs and share dilution

The 110,000 new shares listed on November 18, 2026 are subject to a lock-up through November 17, 2027. Operating cash flow was -KRW 20.5 billion in 2025, so the possibility of further fundraising remains. After the lock-up ends in November 2027, the tradable share volume could change.

11

What to watch next

  1. Late March 2027

    The 2026 annual report deadline. This is the point to check whether 2026 full-year revenue reached the company's KRW 3 billion target and whether the 60% second-half gross margin target was met.

  2. Mid-May 2027

    The Q1 2027 quarterly report deadline. This is the point to check how much purchase-conditional placements converted into recognized sales and the trend in gross margin.

  3. After November 18, 2027

    The lock-up on the 110,000 third-party allotment shares ends. This is the point to check whether tradable volume increases.

  4. Late March 2028

    The 2027 annual report deadline. This is the point to check whether the company's target of an annual profit in 2027 was achieved.

12

Overall view

Noul recorded KRW 5.12 billion in revenue in 2025, the largest year in the 2022 to 2025 span, but the operating loss of KRW 20.1 billion and operating cash flow of -KRW 20.5 billion persisted. Quarterly revenue in 2026 moved between KRW 322 million, KRW 1.01 billion and KRW 512 million, showing wide swings.

The company has set a 500-unit device guidance and a 2027 annual profit target, and whether purchase-conditional placements convert into recognized sales is the key test. On the positive side are gross margin improvement, expanding overseas approvals and a confirmed government support grant.

On the negative side are cumulative losses, revenue reliant on leading indicators, and capital burdens tied to the rights issue and administrative issue designation risk.

The loss attributable to controlling shareholders over the last four quarters totaled KRW 20.8 billion, and the debt ratio fell to 52.7% in 2025 from 87.5% in 2024. The next checkpoints are the revenue and operating loss in the 2026 annual report and the pace of revenue conversion shown in the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. comp.fnguide.com
  3. kind.krx.co.kr
  4. kind.krx.co.kr
  5. sisamagazine.co.kr
  6. selfetf.com
  7. topstarnews.net
  8. k5.co.kr
  9. markets.hankyung.com
  10. investing-for-everyone.com
  11. view.asiae.co.kr
  12. srtimes.kr
  13. koriscience.com
  14. m.news.nate.com
  15. clinicaltrials.gov
  16. ncbi.nlm.nih.gov
  17. arxiv.org
  18. ncbi.nlm.nih.gov

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis